Search by Drug Name or NDC

    NDC 50991-0121-15 Polytussin DM 2; 15; 7.5 mg/5mL; mg/5mL; mg/5mL Details

    Polytussin DM 2; 15; 7.5 mg/5mL; mg/5mL; mg/5mL

    Polytussin DM is a ORAL LIQUID in the HUMAN OTC DRUG category. It is labeled and distributed by Poly Pharmaceuticals,. The primary component is DEXBROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 50991-0121
    Product ID 50991-121_cf4c931c-d9e1-8599-e053-2995a90a2623
    Associated GPIs 43995803500930
    GCN Sequence Number 076700
    GCN Sequence Number Description d-methorphan/pe/dexbromphenir LIQUID 15-7.5-2/5 ORAL
    HIC3 B3R
    HIC3 Description NON-OPIOID ANTITUS-1ST GEN.ANTIHISTAMINE-DECONGEST
    GCN 42443
    HICL Sequence Number 025559
    HICL Sequence Number Description DEXTROMETHORPHAN HBR/PHENYLEPHRINE HCL/DEXBROMPHENIRAMINE
    Brand/Generic Brand
    Proprietary Name Polytussin DM
    Proprietary Name Suffix n/a
    Non-Proprietary Name Dexbrompheniramine Maleate, Dextromethorphan HBr, Phenylephrine HCl
    Product Type HUMAN OTC DRUG
    Dosage Form LIQUID
    Route ORAL
    Active Ingredient Strength 2; 15; 7.5
    Active Ingredient Units mg/5mL; mg/5mL; mg/5mL
    Substance Name DEXBROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name Poly Pharmaceuticals,
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2022-12-31

    Package

    NDC 50991-0121-15 (50991012115)

    NDC Package Code 50991-121-15
    Billing NDC 50991012115
    Package 15 mL in 1 BOTTLE (50991-121-15)
    Marketing Start Date 2021-10-20
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL cf4c931c-d9e0-8599-e053-2995a90a2623 Details

    Revised: 10/2021